SCHEMBL2712974

SCHEMBL2712974

COc1ccccc1-c1ncccc1Nc1c(C)c(-c2ccccn2)nc2cc(F)cc(F)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.38
TGFBR1 P36897 3/20 0.38
IDO1 P14902 1/20 0.37
GRM5 P41594 1/20 0.37
PIK3CA P42336 2/20 0.37
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
TDO2 P48775 1/20 0.36
FFAR1 O14842 1/20 0.35
USP2 O75604 2/20 0.35
CYP1A2 P05177 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2712428 0.91 PIK3CD (0.44) PIK3CDL3MBTL1TGFBR1IDO1GRM5
SCHEMBL2711897 0.90 PIK3CD (0.54) PIK3CDL3MBTL1TGFBR1IDO1GRM5
SCHEMBL2712834 0.89 PIK3CD (0.52) PIK3CDL3MBTL1TGFBR1GRM5PIK3CA
SCHEMBL2713223 0.83 PIK3CD (0.75) PIK3CDPIK3CA
SCHEMBL3774912 0.80 PIK3CD (0.59) PIK3CDPIK3CA
SCHEMBL2712521 0.77 PIK3CD (0.51) PIK3CDL3MBTL1PIK3CAKDM4ENPC1
SCHEMBL2712519 0.77 PIK3CD (0.72) PIK3CDPIK3CA
SCHEMBL2711628 0.76 PIK3CD (0.74) PIK3CDPIK3CA
SCHEMBL2710923 0.75 PIK3CD (0.59) PIK3CDL3MBTL1TGFBR1PIK3CAALDH1A1
SCHEMBL2713104 0.75 PIK3CD (0.62) PIK3CDPIK3CAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445886-B1 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS AMGEN INC (US) 2016-03-30 EP disclosed
EP-2445886-B1 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS AMGEN INC (US) 2016-03-30 EP disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
EP-2445886-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen, Inc (US) 2012-05-02 EP disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
WO-2010151791-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151791-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 14/4885L3MBTL1 2963/4885TGFBR1 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.